PHVS
Price
$30.68
Change
+$0.02 (+0.07%)
Updated
Oct 22 closing price
Capitalization
2.15B
20 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$92.33
Change
-$0.62 (-0.67%)
Updated
Oct 22 closing price
Capitalization
8.14B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PHVS vs SYRE

PHVS vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
PHVS vs. SYRE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHVS is a StrongBuy and SYRE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PHVS with price predictions
Oct 22, 2026

PHVS in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026

PHVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 34 cases where PHVS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PHVS's RSI Oscillator exited the oversold zone, 16 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for PHVS just turned positive on October 20, 2026. Looking at past instances where PHVS's MACD turned positive, the stock continued to rise in 42 of 55 cases over the following month. The odds of a continued upward trend are 76%.

Following a +11.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHVS advanced for three days, in 193 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHVS as a result. In 90 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

PHVS moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PHVS crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for PHVS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.160) is normal, around the industry mean (2.973). P/E Ratio (-11.800) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. PHVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for SYRE with price predictions
Oct 22, 2026

SYRE in upward trend: price rose above 50-day moving average on October 21, 2026

SYRE moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 68 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.

Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.527) is normal, around the industry mean (2.973). P/E Ratio (-48.104) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
25
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
34
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHVSSYRE
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (PHVS: $30.68 vs. SYRE: $92.33)
Brand notoriety: PHVS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHVS: 38% vs. SYRE: 38%
Market capitalization -- PHVS: $2.15B vs. SYRE: $8.14B
PHVS [@Biotechnology] is valued at $2.15B. SYRE’s [@Biotechnology] market capitalization is $8.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHVS’s FA Score shows that 2 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).

  • PHVS’s FA Score: 2 green, 3 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, SYRE is a better buy in the long-term than PHVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHVS’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • PHVS’s TA Score: 4 bullish, 6 bearish.
  • SYRE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than PHVS.

Price Growth

PHVS (@Biotechnology) experienced а +3.51% price change this week, while SYRE (@Biotechnology) price change was +15.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

PHVS is expected to report earnings on Nov 11, 2026.

SYRE is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PHVS
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ABLS21.50N/A
N/A
Abacus FCF Small Cap Leaders ETF (ABLS)
ZMAY26.42-0.05
-0.17%
Innovator Equity Defined Protection ETF - 1 Yr May (ZMAY)
JHML90.41-0.70
-0.77%
John Hancock Multifactor Large Cap ETF (JHML)
QSIX41.29-1.17
-2.77%
Pacer Metaurus Nasdaq 100 Dividend Multiplier 600 ETF (QSIX)
SRV38.14-1.49
-3.76%
NXG Cushing Midstream Energy Fund